Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Net Income (2019 - 2025)

Historic Net Income for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to -$112.7 million.

  • Beam Therapeutics' Net Income fell 1661.36% to -$112.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$414.9 million, marking a year-over-year decrease of 20228.73%. This contributed to the annual value of -$376.8 million for FY2024, which is 18424.88% down from last year.
  • Per Beam Therapeutics' latest filing, its Net Income stood at -$112.7 million for Q3 2025, which was down 1661.36% from -$102.3 million recorded in Q2 2025.
  • Beam Therapeutics' Net Income's 5-year high stood at $142.8 million during Q4 2023, with a 5-year trough of -$200.4 million in Q1 2021.
  • Over the past 5 years, Beam Therapeutics' median Net Income value was -$89.0 million (recorded in 2023), while the average stood at -$76.3 million.
  • In the last 5 years, Beam Therapeutics' Net Income plummeted by 62193.24% in 2021 and then surged by 47227.31% in 2023.
  • Over the past 5 years, Beam Therapeutics' Net Income (Quarter) stood at -$64.7 million in 2021, then surged by 40.73% to -$38.3 million in 2022, then skyrocketed by 472.27% to $142.8 million in 2023, then crashed by 163.33% to -$90.4 million in 2024, then dropped by 24.68% to -$112.7 million in 2025.
  • Its Net Income was -$112.7 million in Q3 2025, compared to -$102.3 million in Q2 2025 and -$109.4 million in Q1 2025.